IP Library Granted Patent US 7,538,094
Granted Patent B2
US 7,538,094 · App. 10/882,358 · Granted May 26, 2009

Composition containing ribavirin and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,538,094
App. No.
10/882,358
Granted
May 26, 2009
Kind
B2
Abstract

Ribavirin formulations are disclosed for use in capsules or tablets as well as processes for their preparation and methods for their administration.

Claims (32)

1. A process of forming ribavirin particles, the process comprising:

mixing ribavirin with at least one excipient to form a mixture;

adding water to the mixture in an amount of from about 15 wt % to about 80 wt % based on the total weight of the mixture to form a wet granulated mixture; and

drying the wet granulated mixture to form ribavirin containing particles.

2. The process according to claim 1 , wherein the water is added at a rate of about 2 kg per minute to about 50 kg per minute.

3. The process according to claim 1 , wherein said drying step comprises heating the wet granulated mixture to a temperature ranging from about 35° C. to about 45° C., until the particles contain a moisture content ranging from 0.5% to 5.0%.

4. The process according to claim 1 further comprising filling a plurality of capsules with the ribavirin containing particles wherein the plurality of capsules have a weight variability of within +/−8% and a ribavirin content with a standard deviation of less than about 4%.

5. The process of claim 1 , further comprising spheronizing the wet granulated mixture prior to the drying step.

6. The process of claim 1 , comprising mixing ribavirin with two or more excipients to form the mixture.

7. The process of claim 1 , wherein the amount of water added to the ribavirin mixture is between about 50 wt % to about 80 wt % based upon the dry ingredients.

8. The process of claim 1 , further comprising forming a dosage form from the ribavirin containing particles.

9. The process of claim 1 , further comprising forming tablets from the ribavirin containing particles.

10. The process of claim 8 , wherein the dosage form contains up to 1200 mg of ribavirin.

11. The process of claim 8 , wherein the dosage form contains 400 mg to 600 mg of ribavirin.

12. The process of claim 1 , further comprising filling a plurality of capsules with the ribavirin containing particles.

13. A process for preparing a ribavirin composition, the process comprising:

mixing ribavirin with at least two excipients to form a mixture;

adding water to the mixture in an amount of from about 15 wt % to about 80 wt % based on the total weight of the mixture to form a wet mixture; and

forming a free flowing ribavirin composition from the wet mixture, wherein the composition has an angle of repose of no higher than about 35 degrees.

14. A process for preparing a free flowing granular ribavirin composition, the process comprising: wet granulating a ribivirin mixture by adding water in an amount of from about 50 wt % or more based on the weight of the mixture and drying the ribavirin mixture to form a free flowing ribavirin composition, wherein the ribavirin composition has an angle of repose no higher than about 35 degrees.

15. The process according to claim 13 wherein forming the free flowing ribavirin composition comprises spheronizing and drying the wet mixture.

16. The process according to claim 13 wherein forming the free flowing ribavirin composition comprises drying and milling the wet mixture.

17. The process according to claim 16 further comprising adding croscarmellose sodium and magnesium stearate to the dried, milled ribavirin composition.

18. The process according to claim 14 further comprising extruding and spheronizing the ribavirin mixture prior to drying the mixture.

19. The process according to claim 14 wherein the ribavirin composition has an angle of repose no higher than about 30 degrees.

20. The process of claim 1 , wherein the mixture contains at least about 70% by weight of ribavirin.

21. The process according to claim 1 wherein ribavirin is mixed with at least one filler and at least one binder to form the mixture.

22. The process of claim 21 , wherein the filler is selected from the group consisting of: lactose monohydrate and microcrystalline cellulose.

23. The process according to claim 1 wherein ribavirin is mixed with at least one filler, at least one disintegrant, and at least one binder to form the mixture.

24. The process of claim 1 wherein the mixing step comprises mixing at least about 70 wt % ribavirin with about 5-25 wt % microcrystalline cellulose, about 1-10 wt % croscarmellose, about 0.5-5 wt % povidone, about 1-15 wt % lactose, or the pharmaceutically acceptable salts or hydrates thereof to form the mixture.

25. The process according to claim 6 further comprising milling the dried ribavirin mixture to form the ribavirin containing particles.

26. The process according to claim 25 further comprising adding a disintegrant and a lubricant to the dried, milled ribavirin containing particles.

Assignments (14)
TERMINATION OF PATENT AND TRADEMARK SECURITY AGREEMENT Recorded Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON PHARMACEUTICALS, LLC
Reel/Frame 051106/0789 →
SECURITY INTEREST Recorded Sep 2, 2015
From: KADMON PHARMACEUTICALS, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036478/0611 →
SECURITY INTEREST Recorded Aug 31, 2015
From: KADMON PHARMACEUTICALS, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036460/0811 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2015
From: MACQUARIE US TRADING LLC
To: KADMON PHARMACEUTICALS, LLC
Reel/Frame 036461/0825 →
SECURITY AGREEMENT Recorded Jun 25, 2013
From: KADMON PHARMACEUTICALS, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030678/0514 →
SECURITY AGREEMENT Recorded Jun 25, 2013
From: KADMON PHARMACEUTICALS, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030678/0620 →
SECURITY AGREEMENT Recorded Nov 23, 2011
From: KADMON PHARMACEUTICALS, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 027280/0954 →
CHANGE OF NAME Recorded Oct 18, 2011
From: THREE RIVERS PHARMACEUTICALS, LLC
To: KADMON PHARMACEUTICALS, LLC
Reel/Frame 027081/0431 →
SECURITY AGREEMENT Recorded Nov 8, 2010
From: THREE RIVERS PHARMACEUTICALS, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 025321/0502 →
RELEASE OF SECURITY INTEREST Recorded Nov 8, 2010
From: SUNTRUST BANK, AS ADMINISTRATIVE AGENT
To: THREE RIVERS PHARMACEUTICALS, LLC
Reel/Frame 025332/0385 →
RELEASE OF SECURITY INTEREST Recorded Jul 15, 2010
From: PNC BANK, NATIONAL ASSOCIATION
To: THREE RIVERS PHARMACEUTICALS, LLC; THREE RIVERS RESEARCH INSTITUTE I, LLC; 3RP INVESTMENT CORPORATION; THREE RIVERS BIOLOGICS, LLC; THREE RIVERS GLOBAL PHARMA, LLC
Reel/Frame 024686/0764 →
SECURITY AGREEMENT Recorded Jul 14, 2010
From: THREE RIVERS PHARAMCEUTICALS, LLC; THREE RIVERS PHARMACEUTICALS, LLC
To: SUNTRUST BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 024678/0603 →
SECURITY AGREEMENT Recorded Jan 15, 2008
From: THREE RIVERS PHARMACEUTICALS, LLC; THREE RIVERS RESEARCH INSTITUTE 1, LLC; 3RP INVESTMENT CORPORATION; THREE RIVERS BIOLOGICS, LLC; THREE RIVERS GLOBAL PHARMA, LLC
To: NATIONAL CITY BANK
Reel/Frame 020362/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2004
From: KERRISH, DONALD J.; BERGERON, JOHN R.; AUGSBURGER, LARRY L.
To: THREE RIVERS PHARMACEUTICALS, LLC
Reel/Frame 015545/0340 →